Cosmo Pharmaceuticals NV

C43

Company Profile

  • Business description

    Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

  • Contact

    Sir John Rogerson’s Quay
    Riverside II
    Dublin2
    IRL

    T: +353 18170370

    E: [email protected]

    https://www.cosmopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    339

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries7,984.00149.10-1.83%
CAC 407,858.8317.53-0.22%
DAX 4022,390.84149.14-0.66%
Dow JONES (US)42,225.32235.360.56%
FTSE 1008,608.4826.32-0.30%
HKSE23,202.534.31-0.02%
NASDAQ17,601.05151.160.87%
Nikkei 22535,725.87101.390.28%
NZX 50 Index12,181.86138.33-1.12%
S&P 5005,670.9737.900.67%
S&P/ASX 2007,785.20149.30-1.88%
SSE Composite Index3,350.131.690.05%

Market Movers